본문
DigmBio, led by CEO Kim Jeong-min, has been selected for the prestigious '2021 Dementia Overcoming Research and Development Project' backed by the Ministry of Science and ICT and the Ministry of Health and Welfare. Their research topic focuses on developing a new non-clinical candidate for Alzheimer's treatment targeting TASR GPCR.
Their preliminary candidate material, DM3100, has shown promising results with brain cell protection and regenerative abilities, outperforming existing dementia drugs like donepezil. CEO Kim emphasizes the urgency for fundamental treatments as previous approaches based on the beta-amyloid hypothesis have faced clinical setbacks.
With this support, DigmBio aims to advance early discovery of non-clinical candidate substances and potentially export the technology. Established last year, Dime Bio boasts a strong R&D team, including Chief Technology Officer Jae-Hoon Kang and Nam-gyu Lee, both with extensive experience in the pharmaceutical industry.
Click here to read Korean version
Their preliminary candidate material, DM3100, has shown promising results with brain cell protection and regenerative abilities, outperforming existing dementia drugs like donepezil. CEO Kim emphasizes the urgency for fundamental treatments as previous approaches based on the beta-amyloid hypothesis have faced clinical setbacks.
With this support, DigmBio aims to advance early discovery of non-clinical candidate substances and potentially export the technology. Established last year, Dime Bio boasts a strong R&D team, including Chief Technology Officer Jae-Hoon Kang and Nam-gyu Lee, both with extensive experience in the pharmaceutical industry.
Click here to read Korean version